Archive / SP SAP Drug Development

RSS feed for this section

Veterinary Development of Substance P-Saporin (SP-SAP)

A quick update on the pursuit of conditional approval of SP-SAP to  treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon […]

Veterinary Development of Substance P-Saporin (SP-SAP)

A groundbreaking pain therapeutic is poised for conditional approval in 2015 to treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon […]

dog_otis2

Otis Gets His Wag Back!

Dog with bone cancer jumps for joy over new treatment that made him pain-free after one dose! Otis, the golden retriever, was in his golden years when bone cancer pain threatened to shorten his life. As a participant in a clinical trial aimed at pet dogs, he was given a single treatment with a pain […]

dog_otis

Cancer Pain Relief in Pet Dogs has Direct Translation into Human Chronic Pain Conditions

Based on the recent publication by: Brown DC, Agnello K. (2013) Intrathecal substance p-saporin in the dog: efficacy in bone cancer pain. Anesthesiology 119(5):1178-1185 and the October 2013 press release by the American Society of Anesthesiologists, “Man’s best friends’ chronic pain relieved with new treatment, study finds: Findings could be useful to human cancer patients.” […]

Cover Article: FDA Gives Green Light to Human Clinical Trials for Cancer Pain

Contributed by Douglas A. Lappi, Ph.D., President/Chief Scientific Officer, Advanced Targeting Systems, San Diego, CA Substance P-Saporin (SP-SAP), ATS’s patented conjugate being developed for cancer pain therapy, has attracted a considerable amount of attention recently. Back-to-back publications, a press release and editorial were featured in the November issue of the journal Anesthesiology. The first article, […]

$3 Million Award from National Cancer Institute

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI). Representatives from the NCI stated that the Advanced Targeting Systems proposal was ranked #1 […]

Photo Credit: Scott Rogers, Joe Ghilardi, Patrick Mantyh (University of Minnesota)

Targeted Therapy for Chronic Pain

In 1997, SP-SAP (a chemical conjugate of Substance P and the ribosome-inactivating protein saporin) was created to eliminate Substance P receptor (SPR) neurons that propagate the signal for chronic pain. ATS has successfully completed preclinical studies, safety tests in animal models and a GLP toxicology study in rat, funded both internally and by the National […]

SP-SAP Drug Development Update

Substance P-Saporin (SP-SAP) is a drug candidate that eliminates the spinal cord neurons that send the chronic pain signal to the brain. SP-SAP has been tested in a variety of animal models and proven effective in permanently eliminating the perception of chronic pain. ATS has completed extensive preclinical studies, a GLP toxicology study, and a […]

Chronic Pain Drug – Update on SP-SAP Development

ATS continues to make progress toward human clinical trials with SP-SAP. Thanks to the financial support of the National Institutes of Health, National Institute of Mental Health, preclinical studies have been completed, protocols for drug production have been written and the first of two toxicology studies is done. This first study is a GLP toxicology […]

SP-SAP: How It’s Different From Substance P Antagonists

As most of you know, SP-SAP is a potential therapeutic that ATS is developing for use in the elimination of chronic pain. For the past seven years, preclinical studies have been carried out in the rat, safety and dosing studies completed in the dog and the first of two toxicology studies has begun in the […]